Related Experiment Video
Updated: Aug 10, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Prolonged intake of chlorambucil for ovarian cancer
A M Khalil1, R A Khatib, A I Shamseddine
1Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Lebanon.
Abstract:
The use of alkylating agents has been reported to be a cause of secondary leukemia particularly in patients surviving for 2 years or more after treatment of ovarian carcinoma. The risk of developing leukemia is possibly related to the duration of treatment and the total dose of alkylating agents administered. We report a patient with epithelial ovarian carcinoma who received chlorambucil for 130 consecutive months with no clinical or laboratory evidence of leukemia.
Related Concept Videos
Oogenesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

